The Current State of Knowledge About Evolution of Multiple Myeloma to Plasma Cell Leukemia.
Diagnosis
Plasma cell dyscrasia
Prognosis
Secondary plasma cell leukemia
Therapy
Journal
Clinical lymphoma, myeloma & leukemia
ISSN: 2152-2669
Titre abrégé: Clin Lymphoma Myeloma Leuk
Pays: United States
ID NLM: 101525386
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
received:
10
07
2022
revised:
20
11
2022
accepted:
02
12
2022
pubmed:
3
1
2023
medline:
3
3
2023
entrez:
2
1
2023
Statut:
ppublish
Résumé
Plasma cell leukemia is a rare form of multiple myeloma (MM). In contrast to de novo primary plasma cell leukemia (pPCL), which is very uncommon presentation of MM, there is increasing frequency of transformation to secondary plasma cell leukemia (sPCL) with increasing survival of patients (MM). The molecular basis of sPCL remains poorly understood sPCL is particularly aggressive and is associated with an extremely poor prognosis, constituting a major unmet medical need. High-quality data in sPCL regarding presentation, treatment and outcomes is limited. Herein we review the current state of knowledge on sPCL diagnostics, molecular biology, clinical characteristics, prognosis and reported treatment outcomes and the emergence of the new therapeutic strategies.
Identifiants
pubmed: 36593169
pii: S2152-2650(22)01747-5
doi: 10.1016/j.clml.2022.12.002
pii:
doi:
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
188-193Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.